$BIOL Company has good fundamentals, but its price and the unchanging balance sheet bring up a significant problem: they may soon be forced to do a RS to avoid delisting from NASDAQ. RS is rarely good for a stock's price...don't be fooled by the fact that 5 million shares were sold (listed as "insider trading") because it was not a corporate director but simply a 10% investor, who took his profits at .55...Company directors have actually been purchasing the stock through special-offers, which is a plus. But the RS looms large. Best advice: wait until RS and then see where the stock price goes.